Bharat Biotech aims at billion Covaxin doses a year, phase-3 trials in Oct

Firm also ties up with Washington University's school of medicine for intransal vaccine for Covid-19

Bharat Biotech plans to start phase-3 clinical trials of its indegeniously developed Covid-19 vaccine (Covaxin) in October and is in talks with partners to expand its manufacturing footprint to produce one billion doses annually.

The company, on Wednesday, also announced a tie-up with Washington University's school of medicine to develop a novel intransal vaccine for Covid-19 that would enable to overcome challenges in dosage administration. The company will also distribute the intransal vaccine in all markets except US, Japan and Europe.

"We have completed phase I clinical trials of Covaxin and are getting ready to submit data to the Drug